glp-1/gip/glucagon triple agonist name Main physiological actions of the dual GIP and GLP-1 Schematic illustration of monoagonists, dual
Description
The OR for achieving a weight loss of at least 5% with tirzepatide 5 mg, 10 mg and 15 mg (vs GLP-1 RAs) was, respectively, 1.96 (95% CI 1.01, 3.80 [ I 2 61%]), 4.79 (95% CI 1.95, 11.73 [ I 2 74%]) and 4.57 (95% CI 3.38, 6.18 [ I 2 0%]) (ESM Table 2)
GLP-1 utilization isn't slowing downand employers are feeling the impact
Melmed, S
Repeat freeze-thaw cycles should be avoided because peptide bond degradation and aggregation can compromise assay results
This is more about capitalizing on a trend than providing solutions supported by scientific evidence
J Diabet Invest 7(suppl 1):812
